

392

European Medicines Agency  
Domenico Scarlattilaan 6,  
1083 HS Amsterdam

**Radboud university medical center**  
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen  
The Netherlands  
Internal postal code 392  
Philips van Leydenlaan 15  
Radboudumc entrance west, route 392  
T +31 24 366 83 33

Manager Policy, Quality and Support  
mrs. J.A.H. Droste, PhD  
rtclinicalstudies@radboudumc.nl  
www.radboudumc.nl

Date	Our reference	Page
30 June 2022	AN/GR	1 of 1
Your reference	Contact RTC Clinical Studies	

Dutch Chamber of Commerce  
trade register 80262783

Subject:

Results posting of EudraCT **2007-005789-11**; "Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?"

Dear EMA,

On behalf of the Prof. dr. G.A.P.J.M. Rongen as Principal Investigator of this study, I hereby confirm that screening and inclusion of subjects in the following clinical trial protocol: "Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?" with EudraCT number 2007-005789-11 (favourable opinion by the Ethics Committee on March 11th 2008), **was never started**.

**The reason for this was to lack of availability of Annexin A5 (essential to measure the primary outcome of this trial).**

The Declaration End of Trial Form B7 reported "Completed", but this should be "**Prematurely Ended**".

We hope this information is sufficient to finalize results posting.

With kind regards,

Arjan Nootboom,  
Research Consultant at RTC Clinical Studies  
Radboudumc  
[rtclinicalstudies@radboudumc.nl](mailto:rtclinicalstudies@radboudumc.nl)

cc Prof.dr. G.A.P.J.M Rongen